Neuropeutics
San Diego, United States· Est.
A private biotech leveraging proprietary TDP‑43 targeting to develop disease‑modifying therapies for neurodegenerative disorders.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
A private biotech leveraging proprietary TDP‑43 targeting to develop disease‑modifying therapies for neurodegenerative disorders.
Neurodegenerative Diseases
Technology Platform
Proprietary cellular and animal models targeting TDP‑43 aggregation, with a small‑molecule (JRMS‑22) that leverages a non‑canonical function of an undisclosed protein to reverse toxic protein aggregation.
Opportunities
First‑in‑class TDP‑43 aggregation reversal could address a major unmet need across multiple neurodegenerative diseases, offering platform potential for expansion beyond ALS.
Risk Factors
Preclinical data may not translate to human efficacy; substantial funding required for IND and clinical trials; competition from larger firms with alternative modalities.
Competitive Landscape
Competes with biotech and pharma firms developing ALS and neurodegeneration therapies (e.g., Biogen, Roche), but differentiates by directly targeting TDP‑43 pathology, a novel upstream mechanism.